Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For DupixentInvestors Business Daily • 09/27/24
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPDGlobeNewsWire • 09/27/24
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPDGlobeNewsWire • 09/27/24
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)GlobeNewsWire • 09/27/24
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPDGlobeNewsWire • 09/27/24
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024GlobeNewsWire • 09/26/24
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron InvestorsSeeking Alpha • 09/25/24
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of EyleaZacks Investment Research • 09/24/24
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine EyleaInvestors Business Daily • 09/23/24
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label ExpansionZacks Investment Research • 09/23/24
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldGlobeNewsWire • 09/20/24
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldGlobeNewsWire • 09/20/24
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)GlobeNewsWire • 09/13/24
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study GoalsZacks Investment Research • 09/11/24
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety ProfileGlobeNewsWire • 09/11/24
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSUGlobeNewsWire • 09/11/24
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)GlobeNewsWire • 09/11/24
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyGlobeNewsWire • 09/11/24
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal TrialGlobeNewsWire • 09/11/24